Tejas Savant
Stock Analyst at Morgan Stanley
(2.26)
# 2,654
Out of 4,944 analysts
233
Total ratings
40.77%
Success rate
-2.99%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Overweight | $65 → $68 | $66.34 | +2.50% | 4 | Aug 12, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $17 | $12.81 | +32.71% | 15 | Aug 12, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $100 → $105 | $97.38 | +7.83% | 9 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Equal-Weight | $15 → $12 | $12.66 | -5.21% | 20 | Aug 4, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $65 → $69 | $67.95 | +1.55% | 10 | Jul 31, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $10 → $8 | $6.08 | +31.58% | 14 | Jul 30, 2025 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $4.03 | +73.70% | 9 | May 28, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $8.49 | -17.55% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $12.66 | -28.91% | 12 | May 5, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.69 | +85.87% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $33.60 | -40.48% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $159.81 | +15.76% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $185.91 | +34.47% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $477.41 | +42.02% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $21.83 | +5.36% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $28.77 | -2.68% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $6.03 | +248.26% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.21 | +65.29% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $11.56 | +246.02% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.71 | +741.63% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.08 | +224.68% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.68 | +2.61% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $4.57 | +9.41% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.21 | +353.51% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $55.10 | +32.49% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $152.75 | +63.67% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.41 | +1,116.55% | 5 | May 12, 2022 |
Tempus AI
Aug 12, 2025
Maintains: Overweight
Price Target: $65 → $68
Current: $66.34
Upside: +2.50%
10x Genomics
Aug 12, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $12.81
Upside: +32.71%
Illumina
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $97.38
Upside: +7.83%
Avantor
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $12.66
Upside: -5.21%
Hologic
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $65 → $69
Current: $67.95
Upside: +1.55%
NeoGenomics
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $6.08
Upside: +31.58%
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.03
Upside: +73.70%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $8.49
Upside: -17.55%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $12.66
Upside: -28.91%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.69
Upside: +85.87%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $33.60
Upside: -40.48%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $159.81
Upside: +15.76%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $185.91
Upside: +34.47%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $477.41
Upside: +42.02%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $21.83
Upside: +5.36%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $28.77
Upside: -2.68%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $6.03
Upside: +248.26%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.21
Upside: +65.29%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $11.56
Upside: +246.02%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.71
Upside: +741.63%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.08
Upside: +224.68%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.68
Upside: +2.61%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.57
Upside: +9.41%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.21
Upside: +353.51%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $55.10
Upside: +32.49%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $152.75
Upside: +63.67%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.41
Upside: +1,116.55%